Christopher Garris

TL;DR: In this article, the authors showed that autochthonous tumors that lacked T-cell infiltration and resisted current treatment options could be successfully sensitized to host antitumor T-cells immunity when appropriately selected immunogenic drugs (e.g., oxaliplatin combined with cyclophosphamide for treatment against tumors expressing oncogenic Kras and lacking Trp53) were used.

TL;DR: The ability of rationally engineered drug–nanoparticle combinations to efficiently modulate tumour-associated macrophages for cancer immunotherapy is demonstrated and R848, an agonist of the toll-like receptors TLR7 and TLR8 identified in a morphometric-based screen, is a potent driver of the M1 phenotype in vitro.

TL;DR: It is found that activating the non‐canonical NF‐&kgr;B transcription factor pathway amplified IL‐12‐producing DCs and sensitized tumors to anti‐PD‐1 treatment, suggesting a therapeutic strategy to improve responses to checkpoint blockade.

TL;DR: In vivo imaging is used to uncover the fate and activity of aPD-1 mAbs and identify specific Fc/FcγR interactions that can be modulated to improve checkpoint blockade therapy.

TL;DR: Track melanoma-derived vesicles at organismal, cellular, and molecular scales to show that endogenous tEVs efficiently disseminate via lymphatics and preferentially bind subcapsular sinus (SCS) CD169+ macrophages in tumor-draining lymph nodes (tdLNs) in mice and humans.